Grant: Collaborative Research and Development Grants
University of Ottawa
$90,000.00
Role of a Novel Probiotic in Immune Homeostasis and the Involvement of microRNAs at Brain and Gut Levels_x000d_ _x000d_
FY 2020-21
Summary
Numerous studies are currently undergoing in labs to create novel probiotic-based treatment options for immune homeostasis maintenance that favourably modulate the gut microbiota and influence on neuroinflammation associated with brain disease. Probiotics are widely used for anti-inflammatory activities beyond the gut. We have isolated a novel probiotic bacterium that is able to release bioactive polyphenols after biofermentation of blueberry. These polyphenols are considered the next generation of effective prebiotics by enhancing functional microbiota and contributing to the systemic control of inflammatory markers.
At the intestinal level, there is a fine balance between gut microbiota, microRNAs, and the host immune system. At the brain level, the hypothalamic-pituitary-adrenal axis function is regulated by inflammation. MicroRNAs are also involved in controlling neuroinflammation. In this bidirectional communication between gut and the brain, we postulate that our probiotic is able to modulate gut microbiota, influencing on microRNAs and controlling immune homeostasis and inflammatory markers at the level of the gut and the brain and subsequently behavioural and psychological outcomes. Accordingly, we aim to evaluate the effect of a novel probiotic on improving gut mucosal immunity and microbiota and on analyzing its effect on inflammatory markers and microRNAs at the brain level. We are also aiming to evaluate if the anti-inflammatory effect of the novel probiotic and if its effects will translate in behavioural changes. To achieve these aims, in animal model, we will study mucosal and systemic immunity, change in microRNAs and microbiota. We will use the model of inflammation induced by LPS to study the effect on neuroinflammation and on changes on behaviours as well.
This project will certainly help ascertain the probiotic aspect of the novel bacterium. It will provide a fundamental mechanism by which probiotics modulate systemic anti-inflammatory and protective effects. It may lead to tailored/targeted strategies in mitigating depressive-like syndromes.
Program
Collaborative Research and Development Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
532223-2018
Name nom
Matar, Chantal
Department département
Health Sciences, Faculty of
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2018
Award amount
90000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6100
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food science and technology
Research subject fr
Science et technologie de l'alimentation
Installment
inst:2 - 2
Partie
1
Nb partie
2
Application title
Role of a Novel Probiotic in Immune Homeostasis and the Involvement of microRNAs at Brain and Gut Levels_x000d_
_x000d_
Keyword
NSERC
Application summary
Numerous studies are currently undergoing in labs to create novel probiotic-based treatment options for immune homeostasis maintenance that favourably modulate the gut microbiota and influence on neuroinflammation associated with brain disease. Probiotics are widely used for anti-inflammatory activities beyond the gut. We have isolated a novel probiotic bacterium that is able to release bioactive polyphenols after biofermentation of blueberry. These polyphenols are considered the next generation of effective prebiotics by enhancing functional microbiota and contributing to the systemic control of inflammatory markers.
At the intestinal level, there is a fine balance between gut microbiota, microRNAs, and the host immune system. At the brain level, the hypothalamic-pituitary-adrenal axis function is regulated by inflammation. MicroRNAs are also involved in controlling neuroinflammation. In this bidirectional communication between gut and the brain, we postulate that our probiotic is able to modulate gut microbiota, influencing on microRNAs and controlling immune homeostasis and inflammatory markers at the level of the gut and the brain and subsequently behavioural and psychological outcomes. Accordingly, we aim to evaluate the effect of a novel probiotic on improving gut mucosal immunity and microbiota and on analyzing its effect on inflammatory markers and microRNAs at the brain level. We are also aiming to evaluate if the anti-inflammatory effect of the novel probiotic and if its effects will translate in behavioural changes. To achieve these aims, in animal model, we will study mucosal and systemic immunity, change in microRNAs and microbiota. We will use the model of inflammation induced by LPS to study the effect on neuroinflammation and on changes on behaviours as well.
This project will certainly help ascertain the probiotic aspect of the novel bacterium. It will provide a fundamental mechanism by which probiotics modulate systemic anti-inflammatory and protective effects. It may lead to tailored/targeted strategies in mitigating depressive-like syndromes.